

Prous Science Drug News & Perspectives

FILE DESCRIPTION

The **Prous Science Drug News & Perspectives** database, produced by Prous Science Publishers, allows quick and easy consultation of the latest drug news. The Prous Science Drug News & Perspectives database contains all articles and texts published from selected sections (see Subject Coverage) of the printed journal, *Prous Science Drug News & Perspectives*, plus unpublished records from the journal's sections: "Line Extensions," "R&D Briefs," and "People on the Move." Unpublished records, omitted from the printed journal due to space limitations, are labeled "unpublished" and do not have volume, issue, or page numbers. Unpublished records may also include those in preparation for print. These records will have volume, issue and page numbers added in a later update to the database.

SUBJECT COVERAGE

The Prous Science Drug News & Perspectives database contains the following journal sections:

- **Discovery Line.** A look at efforts in new drug discovery. Coverage: June 1993.
- **Licensing Line.** Short summaries on new technology for licensing from various public and private sources. Coverage: January 1995 - September 2003.
- **Line Extensions.** New uses, combinations and formulations of known drugs, including those launched and under development. Coverage: April 1993 - October 1994.
- **New Product Intros.** New products recently launched on their first markets, including generic and brand names, action, indication, presentation, and source. Coverage: March 1995 - March 2004.
- **People on the Move.** Organizational and personnel changes in the pharmaceutical industry. Coverage: January 1993 - November 1998.
- **R&D Briefs.** Information on products progressing through the drug discovery and development pipeline throughout the world. Coverage: January 1992 - June 2005.
- **The Year's New Drugs.** Annual articles that offer a historical and research perspective on new products that reached their first markets. A guide to

developments in drug therapy, highlighting new generation compounds with therapeutic gains over existing drugs and new therapeutic entities arising from innovative approaches to drug research.

Coverage: January 1988 - March 2004.

SOURCES

The full-text entries in the Prous Science Drug News & Perspectives database are prepared from information compiled from current literature, conferences, company communications, and scientific contributions.

DIALOG FILE DATA

Inclusive Dates:

January 1992 to 2005 (see "Subject Coverage" for coverage dates for each journal section).

Update Frequency: Closed

File Size: 33,888 records as of November 2005

CONTACT

Prous Science Drug News & Perspectives is produced by Prous Science Publishers. Questions concerning file content should be directed to:

Prous Science

P.O. Box 540

Barcelona 08080

Spain

Phone: +34 93 459-2220

Fax: +34 93 458-1535

E-Mail: service@prous.es

The Year's New Drugs Section

DIALOG(R)File 455:Prous Science Drug News & Perspectives
(c) 2000 J.R. Prous, S.A. All rts. reserv.

00238215 (THIS IS THE FULLTEXT)

THE YEAR'S NEW DRUGS, 1993

Drug News & Perspectives, The Years New Drugs Section, v7, n1, p26
January 26 1994

DOCUMENT TYPE: Journal LANGUAGE: English RECORD TYPE: FullText
WORD COUNT: 3,686

/TI
JN=, /SH, SH=
PD=, PY=
DT=, LA=, RT=

/XT, /TX

TEXT: Inaugurated six years ago, this annual section provides the opportunity to present from both a historical and a research perspective those molecular entities and biological drugs that were launched in various countries for the first time during the past year.

Without exceeding space limitations, information on these drugs is presented to serve as a guide to the most recent developments in drug therapy, highlighting new-generation compounds with therapeutic gains over existing drugs and new therapeutic entities arising from innovative approaches to drug research. New indications for known drugs and new formulations are also included.

/TX

According to our records, 44 new molecular entities and biological drugs and 3 diagnostic agents first reached the market in 1993, a figure that represents a decrease with respect to the previous year (Table I). During the past year, antiinfective agents represented the most active group in terms of total launches, followed by central nervous system drugs. Japan was the most active market for new products, with a total of 21 launches in 1993, representing 49% of the total of new introductions for the year.

(...)

CENTRAL NERVOUS SYSTEM DRUGS

Psychopharmacologic drugs

Since the introduction of chlorpromazine in 1952, the dopamine D2 receptor has been the major target for antipsychotic drugs.

(...)

Neurologic drugs

The cholinergic hypothesis of senile dementia proposes that aging is associated with a loss of cholinergic neurotransmission, which is essential for some cognitive functions. The cholinergic hypothesis has led to the development of compounds capable of improving cholinergic transmission within the CNS.

(...)

ANTIARTHRITIC DRUGS

Two new NSAIDs were launched in Japan: ampiroxicam is marketed by Toyama (Nacyl) and Pfizer (Flucam), and the propionic acid derivative zaltoprofen was launched by Zeria (Peon) and Nippon Chemiphar (Soleton).

RESPIRATORY DRUGS

The potent H1-receptor antagonist emedastine difumarate was launched in Japan by Kowa (Remicut) and Kanebo (Daren) for the treatment of allergic rhinitis and urticaria.

(...)

CARDIOVASCULAR DRUGS

Research on angiotensin-converting enzyme (ACE) inhibitors has resulted in the development of important new agents for the treatment of hypertension and heart failure.

(...)

RENAL-UROLOGIC DRUGS

Torsemide (Boehringer Mannheim) is a sulfonyleurea loop diuretic that was introduced last year in Germany (Unat) and Italy (Toradiur) and was approved in the U.S. (Demadex) for the...

(...)

DRUGS AFFECTING BLOOD COAGULATION

Over the last decade, successful attempts have been made to fractionate and depolymerize heparin into fragments of various chain lengths. Low-molecular-weight heparins (LMWHs) inhibit...

(...)

ENDOCRINE DRUGS

Prolactin, a hormone released from the anterior pituitary, regulates lactation. Dopamine D2 agonists have proven effective in preventing or suppressing puerperal lactation, as well as in...

The Year's New Drugs Section (cont'd)

(...)

METABOLIC DRUGS
 Osteoporosis is an important public health problem and is the cause of at least 1.2 million bone fractures in the U.S. each year. Two approaches toward bone mass manipulation have been...
 (...)

GASTROINTESTINAL AGENTS
 As part of a program aimed toward discovering new antiulcer agents with enhanced cytoprotective activity, scientists at Tanabe Seiyaku synthesized a series of dehydroabiatic acid...
 (...)

DERMATOLOGIC DRUGS
 Betamethasone butyrate propionate (Antebate; Torii) was launched last year in Japan as a topical antiinflammatory corticosteroid.
 (...)

IMMUNOLOGIC DRUGS
 A new vaccine that combines Lederle's diphtheria, tetanus and pertussis (DTP) vaccine (Tri-Immunol) with Praxis Biologics' Haemophilus b conjugate vaccine (HibTITER) was launched last year...
 (...)

ANTIINFECTIVE AGENTS
 Thienamycin was isolated in 1979 from Streptomyces cattleya and was found to be highly active against almost all bacteria that are pathogenic in humans...
 (...)

ANTINEOPLASTIC AGENTS
 Cladribine (Leustatin; Ortho Biotech) was launched last year in the United States as a single intravenous treatment for hairy cell leukemia, a rare, often fatal cancer of the blood and bone...
 (...)

DIAGNOSTIC AGENTS
 Last year Shionogi launched Molecular Biosystems' Alburnex injections, which are air-filled microspheres produced by sonication of human serum albumin, in Japan as a contrast agent...
 (...)
 ...Radioisotope for the diagnosis of neuroblastoma, neurocytoma and medullary cancer of the thyroid.
 Copyright (c) 1994 J.R. Prous. All rights reserved.

R&D Briefs Section

DIALOG(R) File 455: Prous Science Drug News & Perspectives
 (c) 2000 J.R. Prous, S.A. All rts. reserv.

00268003 (THIS IS THE FULLTEXT)
 MEDAREX BEGINS PHASE I/II TRIAL of MDX-210 WITH G-CSF
 Drug News & Perspectives, R&D Briefs Section, v7, n8, P 485
 September 29 1994
 DOCUMENT TYPE: Journal LANGUAGE: English RECORD TYPE: Fulltext
 WORD COUNT: 134

/TI
 JN=, /SH, SH=
 PD=, PY=
 DT=, LA=, RT=

/XT, /TX

TEXT: Medarex Inc. announced September 8, 1994, the initiation of a phase I/II clinical trial to evaluate MDX-210, the company's Bispecific(TM) antibody-based therapeutic for the treatment of breast cancer, in combination with granulocyte colony-stimulating factor (G-CSF).
 Preclinical studies indicated that this combination therapy may have the potential to increase the antitumor activity already observed in initial phase I/II clinical trials of MDX-210. Approximately 20 patients with demonstrated resistance to conventional treatments for breast cancer will be enrolled in the trial. The phase I/II will be conducted at the University of Erlangen, Germany, under the direction of Roland Repp, M.D., one of the investigators who led the preclinical studies of the combination therapy. The goal of the phase I/II trial is to evaluate the safety and optimal biological dose of MDX-210 in combination with G-CSF.
 Copyright (c) 1994 J.R. Prous. All rights reserved.

SEARCH OPTIONS

BASIC INDEX

SEARCH SUFFIX	DISPLAY CODE	FIELD NAME	INDEXING	SELECT EXAMPLES
—	—	All Basic Index Fields	Word	S BREAST(W)CANCER
/SH	SH	Section Heading ¹	Word	S R(W)D(W)BRIEFS/SH
/TI	TI	Title	Word	S MDX(W)210/TI
/TX	TX	Text	Word	S BREAST(W)CANCER/TX
/XF	—	All Basic Index Fields Except Full Text	Word	S BISPECIFIC/XF
/XT	XT	Extract	Word	S CLINICAL(W)TRIAL/XT

¹ Searchable in the Basic Index and in the Additional Indexes.

ADDITIONAL INDEXES

SEARCH PREFIX	DISPLAY CODE	FIELD NAME	INDEXING	SELECT EXAMPLES
—	AZ	DIALOG Accession Number		
—	CG	Article Copyright		
DT=	DT	Document Type	Phrase	S DT=JOURNAL
JN=	JN	Journal Name	Phrase	S JN=DRUG NEWS & PERSPECTIVES
LA=	LA	Language ³	Phrase	S LA=ENGLISH
PD=	PD	Publication Date	Phrase	S PD=19940126
PY=	PY	Publication Year	Phrase	S PY=1994
RT=	RT	Record Type ⁴	Phrase	S RT=FULLTEXT
SH=	SH	Section Heading ¹	Phrase	S SH=R&D BRIEFS
—	SO	Source Information ²		
UD=	—	Update	Phrase	S UD=9999
—	WD	Word Count		

² Display Includes journal name, section, volume, issue, pagination, and publication date.

⁴ All records are full-text.

³ All records are in English.

Prous Science Drug News & Perspectives

File 455

SPECIAL FEATURES

For command descriptions, enter HELP LIMIT, HELP SORT, HELP RANK, HELP CURRENT online.

LIMIT	/ENG -- English-Language Articles ³ /FULLTEXT -- Full-Text Records ⁴ /LONG -- Word Count of 1,000 words or more /SHORT -- Word Count of less than 1,000 words /YYYY -- Publication Year	S S1/ENG S ACE(W)INHIBITOR?/FULLTEXT S S2/LONG S S5/SHORT S CHOLINERGIC/2004
SORT	JN, PD, PY, TI	SORT S1/ALL/PY,D PRINT S5/5/1-24/TI
RANK	All phrase- and numeric-indexed fields in the Additional Indexes can be ranked.	RANK PY RANK SH S4
CURRENT	Search only the most recent year plus one (CURRENT1) to five (CURRENT5) years.	B 455 CURRENT2

PREDEFINED FORMAT OPTIONS

NO.	DIALOGWEB FORMAT	RECORD CONTENT
1	--	DIALOG Accession Number
2	--	Bibliographic Citation and Word Count
3	Medium	Bibliographic Citation and Word Count
4	--	Bibliographic Citation, Word Count, and Extract
5	Long	Bibliographic Citation, Word Count, and Extract
6	--	Title, Publication Date, and Word Count
7	--	Bibliographic Citation and Text
8	Free	Title, Publication Date, and Word Count
9	Full	Full Record
K	--	KWIC (Key Word In Context) displays a window of text; may be used alone or with other formats

OTHER OUTPUT OPTIONS

For an explanation, enter HELP TYPE, HELP UDF, HELP TAG online.

USER DEFINED FORMATS	Display codes listed in the Search Options tables can be used to customize output.	TYPE S3/TI,PD/1-5
TAG	Output can be displayed with tags identifying each display field.	TYPE S3/5/1-10 TAG
DIRECT RECORD ACCESS	If the accession number of a specific record is known, it can be used to display the record directly.	TYPE 00238215/5 DISPLAY 00238215/TI,TX PRINT 00238215/9

FOR ONLINE HELP:

See HELP FIELDS 455 for searchable fields; HELP FORMAT 455 for output formats; HELP LIMIT 455 for limits; HELP RATES 455 for cost information; HELP SORT 455 for sorts.